Austar Lifesciences Limited reported a strong earnings rebound for the year ended 31 December 2025, with profit more than doubling despite a slight contraction in gross margin.
Key Financials (YoY) • Revenue rose 2.0% to RMB 1.53 billion. • Gross profit slipped 2.6% to RMB 293.27 million; gross margin eased to 19.2% from 20.1%. • Profit for the year surged 142.30% to RMB 32.88 million; profit attributable to equity holders climbed 110.28% to RMB 33.81 million. • Basic and diluted EPS increased to RMB 0.07 (2024: RMB 0.03). • Operating profit advanced 54.02% to RMB 54.15 million. • Net finance costs fell 25.53% to RMB 10.65 million.
Segment Performance • Integrated Process & Packaging Equipment & Systems (IPS): Revenue up 21.19% to RMB 794.20 million; margin narrowed to 11.5%. • Consulting, Digitalization & Construction (CDC): Revenue down 16.17% to RMB 432.47 million; margin improved to 18.8%. • Life Science Equipment & Consumables (SIC): Revenue down 7.68% to RMB 304.00 million; margin inched up to 39.8%.
Order Momentum and Backlog • 2025 order intake grew 11.4% to RMB 1.93 billion, led by a 28.4% rise in IPS bookings. • Year-end backlog stood at RMB 1.13 billion across 1,572 contracts, with IPS contributing 50.8%, CDC 46.9% and SIC 2.3%.
Cash Flow and Balance Sheet • Net cash from operating activities improved to RMB 132.10 million (2024: RMB 98.81 million). • Cash and cash equivalents increased to RMB 227.39 million (31 Dec 2024: RMB 166.81 million). • Net debt-to-equity ratio dropped to 14.1% (31 Dec 2024: 30.2%), while the gearing ratio declined to 29.4%. • Current ratio edged up to 1.4 from 1.3. • No final dividend was proposed.
Operational Highlights • Delivered 340 projects in 2025 and executed over 820 projects across biopharmaceuticals, chemical preparations and vaccines. • Expanded overseas market reach, establishing five new agency partnerships in the US, Greece, Uzbekistan, Egypt and India. • Added 24 patents during the year, bringing the total patent portfolio to 422. • Advanced R&D in cone-cylinder Nutsche filter dryers, dry granulators, single-use bioreactors and visual inspection systems; TFF ultrafiltration system completed first deployment in India.
Outlook and Strategy According to management, the company will continue leveraging its three-pillar structure (IPS, CDC, SIC), focus on high-growth segments such as bioprocess systems, aseptic filling, continuous manufacturing and contamination-control consumables, and accelerate global expansion through direct investment and local partnerships.
No material post-balance-sheet events were reported.
Comments